Endologix, Inc. (NASDAQ: ELGX) announced that results from its Powerlink XL(R) prospective, multi-center clinical trial met the primary endpoint of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE